Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions.

Autor: Pierre CN; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA.; Duke University School of Medicine, Durham, NC USA., Adams LE; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC USA., Anasti K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC USA., Goodman D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA., Stanfield-Oakley S; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA., Powers JM; Department of Immunology, Duke University, Durham, NC USA., Li D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA., Rountree W; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA.; Department of Medicine, Duke University School of Medicine, Durham, NC USA., Wang Y; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA.; Department of Medicine, Duke University School of Medicine, Durham, NC USA., Edwards RJ; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA.; Department of Medicine, Duke University School of Medicine, Durham, NC USA., Munir Alam S; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA.; Department of Medicine, Duke University School of Medicine, Durham, NC USA., Ferrari G; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA.; Department of Surgery, Duke University School of Medicine, Durham, NC USA.; Department of Molecular Genetics and Microbiology, Duke University, Durham, NC USA., Tomaras GD; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA.; Department of Surgery, Duke University School of Medicine, Durham, NC USA.; Department of Molecular Genetics and Microbiology, Duke University, Durham, NC USA.; Department of Immunology, Duke University, Durham, NC USA., Haynes BF; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA.; Duke University School of Medicine, Durham, NC USA.; Department of Immunology, Duke University, Durham, NC USA., Baric RS; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC USA., Saunders KO; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA.; Department of Surgery, Duke University School of Medicine, Durham, NC USA.; Department of Molecular Genetics and Microbiology, Duke University, Durham, NC USA.; Department of Immunology, Duke University, Durham, NC USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2023 Jul 26. Date of Electronic Publication: 2023 Jul 26.

A tool for evaluating heterogeneity in avidity of polyclonal antibodies.

Autor: Li K; Center for Human Systems Immunology, Duke University, Durham, NC, United States.; Department of Surgery, Duke University, Durham, NC, United States., Dodds M; Integrated Drug Development, Certara, Seattle, WA, United States., Spreng RL; Duke Human Vaccine Institute, Duke University, Durham, NC, United States., Abraha M; Center for Human Systems Immunology, Duke University, Durham, NC, United States.; Department of Surgery, Duke University, Durham, NC, United States., Huntwork RHC; Center for Human Systems Immunology, Duke University, Durham, NC, United States.; Department of Surgery, Duke University, Durham, NC, United States., Dahora LC; Center for Human Systems Immunology, Duke University, Durham, NC, United States.; Department of Immunology, Duke University, Durham, NC, United States., Nyanhete T; Center for Human Systems Immunology, Duke University, Durham, NC, United States.; Department of Immunology, Duke University, Durham, NC, United States., Dutta S; Structural Vaccinology Lab, Malaria Biologics Branch, Walter Reed Army Institute of Research, Silver Spring, MD, United States., Wille-Reece U; PATH's Center for Vaccine Innovation and Access, Washington, DC, United States., Jongert E; GSK Vaccines, Rixensart, Belgium., Ewer KJ; The Jenner Institute, University of Oxford, Oxford, United Kingdom., Hill AVS; The Jenner Institute, University of Oxford, Oxford, United Kingdom.; National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Center, Oxford, United Kingdom., Jin C; Oxford Vaccine Group and Department of Pediatrics, University of Oxford, Oxford, United Kingdom., Hill J; Oxford Vaccine Group and Department of Pediatrics, University of Oxford, Oxford, United Kingdom., Pollard AJ; National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Center, Oxford, United Kingdom.; Oxford Vaccine Group and Department of Pediatrics, University of Oxford, Oxford, United Kingdom., Munir Alam S; Duke Human Vaccine Institute, Duke University, Durham, NC, United States.; Department of Pathology, Duke University, Durham, NC, United States., Tomaras GD; Center for Human Systems Immunology, Duke University, Durham, NC, United States.; Department of Surgery, Duke University, Durham, NC, United States.; Duke Human Vaccine Institute, Duke University, Durham, NC, United States.; Department of Immunology, Duke University, Durham, NC, United States.; Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, United States., Dennison SM; Center for Human Systems Immunology, Duke University, Durham, NC, United States.; Department of Surgery, Duke University, Durham, NC, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Feb 16; Vol. 14, pp. 1049673. Date of Electronic Publication: 2023 Feb 16 (Print Publication: 2023).

Cold sensitivity of the SARS-CoV-2 spike ectodomain

Autor: Edwards, Robert J., Mansouri, Katayoun, Stalls, Victoria, Manne, Kartik, Watts, Brian, Parks, Rob, Janowska, Katarzyna, Gobeil, Sophie M. C., Kopp, Megan, Li, Dapeng, Lu, Xiaozhi, Mu, Zekun, Deyton, Margaret, Oguin, Thomas H., Sprenz, Jordan, Williams, Wilton, Saunders, Kevin O., Montefiori, David, Sempowski, Gregory D., Henderson, Rory, Munir Alam, S., Haynes, Barton F., Acharya, Priyamvada

Publikováno v: Nature Structural and Molecular Biology; February 2021, Vol. 28 Issue: 2 p128-131, 4p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.

Autor: Williams LD; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA., Ofek G; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA., Schätzle S; Department of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA., McDaniel JR; Department of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA., Lu X; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA., Nicely NI; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA., Wu L; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA., Lougheed CS; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA., Bradley T; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Louder MK; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA., McKee K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA., Bailer RT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA., O'Dell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA., Georgiev IS; Vanderbilt Vaccine Center and Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA., Seaman MS; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA., Parks RJ; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA., Marshall DJ; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA., Anasti K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA., Yang G; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA., Nie X; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA., Tumba NL; Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg 2131, South Africa.; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Congella 4013, South Africa., Wiehe K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Wagh K; Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA., Korber B; Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA., Kepler TB; Departments of Microbiology and Mathematics & Statistics, Boston University School of Medicine, Boston, MA 02118, USA., Munir Alam S; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA., Morris L; Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg 2131, South Africa.; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Congella 4013, South Africa., Kamanga G; University of North Carolina Project-Malawi, Kamuzu Central Hospital, Lilongwe, Malawi., Cohen MS; Departments of Medicine, Epidemiology, and Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA., Bonsignori M; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Xia SM; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA., Montefiori DC; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA., Kelsoe G; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA., Gao F; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA., Moody MA; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA., Saunders KO; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA., Liao HX; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA., Tomaras GD; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA., Georgiou G; Department of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA. barton.haynes@dm.duke.edu gg@che.utexas.edu.; Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA., Haynes BF; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. barton.haynes@dm.duke.edu gg@che.utexas.edu.; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA.

Publikováno v: Science immunology [Sci Immunol] 2017 Jan 27; Vol. 2 (7).